PAQ Therapeutics
PAQ Therapeutics is a clinical-stage biotechnology company focused on developing best- and first-in-class KRAS degraders to treat lethal cancers without effective treatment options. Their lead asset, PT0253, is a potent and selective degrader of KRAS G12D, with the first patient dosed in a Phase 1 clinical study in Q1 2025. The company's approach aims to overcome limitations of existing KRAS inhibitors, providing more effective and durable treatments.
Funding Round: Series B
Funding Amount: $39M
Date: 07-May-2025
Investors: Bayland Capital, MRL Ventures Fund (MRLV), Johnson & Johnson Innovation – JJDC, Inc., LAV Fund, BioTrack Capital, Sherpa Health Partners
Markets: Biotech, Oncology, Health Care, Therapeutics
HQ: Burlington, Massachusetts, United States
Founded: 2020
Website: https://www.paqtx.com/
LinkedIn: https://www.linkedin.com/company/paq-therapeutics
Crunchbase: https://www.crunchbase.com/organization/paq-therapeutics
Leave a Comment
Comments
No comments yet.